Drdiary

About Drdiary

Drdiary is a South Korean digital healthcare company founded in 2017 by co-founders Song Jae Yoon and Ryu Yeonji. Song's personal experience, having been diagnosed with diabetes at age 17, was a primary motivator for creating the company. He started developing the app as a university project to solve the daily challenges he faced with managing his condition.

The company operates a mobile app-based platform that offers comprehensive services for chronic disease management, with a primary focus on diabetes. The platform allows users to log and analyze critical health data, including blood glucose levels, meals, exercise, and medication. Serving a market of over 3 million diabetes patients in South Korea, the app has become a leading platform in its category, with over 1.7 million downloads. The business model combines a B2C platform with B2B services. Revenue is generated through multiple streams, including an e-commerce platform ('Dr. Diary Mall') that sells healthcare devices like continuous glucose monitors (CGMs), and its own private brand of low-sugar and low-carbohydrate food products called "Muhwadang". The company also offers corporate employee wellness programs and is developing digital therapeutics.

Drdiary has achieved significant growth, surpassing 10 billion won in annual revenue in 2023, a 30% increase from the previous year. The company has successfully raised a total of $17.6M through several funding rounds, including a Series B round of 14.7 billion KRW (~$12.2M) in March 2022. Key investors include Shinhan Financial Group, Smile Gate Investment, and Handok. The company has formed strategic partnerships with Samsung Electronics and Handok to enhance its services and is expanding internationally into markets like Japan, the US, and Vietnam. Drdiary is preparing for an Initial Public Offering (IPO) on the KOSDAQ, planned for 2026.